More Stories

Informist, Saturday, May 23, 2026

 

--Divi's Lab Jan-Mar net profit INR 7.56 bln
--Analysts saw Divi's Lab Jan-Mar net profit at INR 6.98 bln
--Divi's Lab Jan-Mar revenue INR 27.93 bln
--Analysts saw Divi's Lab Jan-Mar revenue at INR 28.32 bln
--Divi's Lab Jan-Mar net profit INR 7.56 bln vs INR 6.67 bln year ago
--Divi's Lab Jan-Mar revenue INR 27.93 bln vs INR 25.36 bln year ago
--Divi's Lab to pay INR 30 per share final dividend
--Divi's Lab final dividend record date Jul 24
--Divi's Lab FY26 net profit INR 26.07 bln vs INR 22.09 bln year ago
--Divi's Lab FY26 revenue INR 103.88 bln vs INR 91.98 bln year ago
--Divi's Lab Jan-Mar forex gain INR 890 mln vs INR 110 mln year ago
 

By Eshitva Prakash

 

MUMBAI – The revenue growth of Divi's Laboratories Ltd. was the slowest in over two years for the quarter ended March. The pharmaceutical company's top line missed the Street view, while its bottom line for the quarter rose more than analysts' projections, supported by a depreciation of the rupee. 

 

The Hyderabad-based active pharmaceutical ingredients, intermediates, and nutraceutical ingredients maker's net profit for the March quarter rose over 13% on year to INR 7.56 billion, above consensus projection of INR 6.98 billion. This marks a sharp improvement sequentially, with its bottom line rising more than 26% quarter on quarter, compared to an almost flat profit growth in Oct-Dec.

 

The company reported revenue growth of just above 10% on year at INR 27.93 billion for the reporting quarter. Analysts had estimated stronger revenue growth, of INR 28.32 billion, in a seasonally strong quarter.  

 

The company's net profit growth was limited by weak revenue growth and total costs, which rose over 12% on year to INR 19.76 billion. Cost of materials consumed jumped nearly 29% on year to INR 11.73 billion. Employee benefit 

expenses rose 8.5% on year to INR 3.70 billion. The company reported a depreciation and amortisation cost of INR 1.20 billion, up over 12% on year. Costs classified under 'other expenses' rose over 9% on year to INR 3.77 billion.

 

The company's 'other income' increased to INR 1.54 billion from INR 870 million a year ago. This income included INR 890 million in foreign exchange gains. In the year-ago quarter, the company received a small fraction of this amount as forex benefit. Divi's Labs is a supplier of high-value, difficult-to-make pharmaceutical products to global pharmaceutical manufacturers, including the top 20 companies known as Big Pharma.

 

For 2025–26 (Apr-Mar), the company reported a net profit of INR 26.07 billion, up more than 18% compared to FY25. Its revenue for the period rose almost 13% to INR 103.88 billion. The company's board approved INR 30 per share as the final dividend for FY26 and set the record date as Jul. 24. On Friday, shares of the company ended 0.4% higher at INR 6,887 apiece on the National Stock Exchange.  End

 

Edited by Vandana Hingorani

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.